Trial Profile
A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Pacritinib (Primary)
- Indications Myelofibrosis; Polycythaemia vera
- Focus Adverse reactions; Therapeutic Use
- Sponsors S*BIO
- 18 Mar 2015 According to a CTI BioPharma Media Release, study design and results are presented in Blood.
- 16 Mar 2015 Results published in the CTI BioPharma Media Release.
- 10 Dec 2013 Pooled analysis of patients with no more than 100,000 platelets/microL at baseline presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.